Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Myasthenia Gravis × Amifampridine × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

thymoglobulin 1 satralizumab 1 rhoA GTP-Binding Protein 1 eculizumab 1 Sugars 1 Steroids 1 Prednisone 1 Methylprednisolone 1 Mesna 1 Immunoglobulins 1 Hizentra 1 Hematopoietic Stem Cell Transplantation 1 Granulocyte Colony-Stimulating Factor 1 Cyclophosphamide 1 CK-2017357 1 Bortezomib 1 Amifampridine 1 Abatacept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03579966 2024-05-07

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Catalyst Pharmaceuticals, Inc.

Phase 3 Terminated

63 enrolled 10 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡